Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
Table 1
Immune status investigations when the patient was 22 years old, prior to starting intravenous immunoglobulin substitution therapy.
Patient’s result
Normal range
IgA (g/L)
0.24
0.70–4.00
IgM (g/L)
<0.30
0.40–2.30
IgG (g/L)
2.74
7.00–16.00
IgG1 (g/L)
2.60
4.90–11.40
IgG2 (g/L)
0.20
1.50–6.40
IgG3 (g/L)
0.50
0.20–1.10
IgG4 (g/L)
0.02
0.08–1.40
Complement AP (%)
115
30–115
Complement CP (%)
128
70–130
Complement MP (%)
145
10–125
Response to pneumococcal polysaccharide vaccination
Severely impaired
Normal
Toxoplasma IgG (IU/mL)
<2
>7.2
Diphtheria antibodies (IU/mL)
0.03
>0.01
Rubella IgG (IU/mL)
11
>10
Tetanus antibodies (IU/mL)
0.38
>0.01
Interpretation of the response to pneumococcal vaccination was based on the 2015 AAAAI/ACAAI criteria. [10]. AP = alternative pathway; CP = classical pathway; MP = lectin pathway.